非在研机构- |
最高研发阶段临床前 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评快速通道 (美国) |
开始日期2021-08-02 |
申办/合作机构 |
开始日期2020-11-05 |
申办/合作机构 |
开始日期2020-09-09 |
申办/合作机构 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
乙型肝炎 | 临床1期 | 美国 | 2020-11-05 | |
慢性乙型肝炎 | 临床1期 | 美国 | 2019-06-26 | |
慢性乙型肝炎 | 临床1期 | 加拿大 | 2019-06-26 | |
丁型肝炎 | 临床前 | 美国 | 2024-07-26 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床1期 | 25 | 憲廠窪餘醖遞衊艱夢鑰(廠齋簾顧淵鬱顧製壓鑰) = Overall, 9 subjects reported 22 treatment emergent adverse events (TEAEs), and all of which were mild except for 4 moderate events (n = 2, placebo [GI disorders and urinary tract infection] and n = 2, 200 mg [anaemia and aPTT prolonged], both unlikely related to study drug). No grade 3 TEAEs or SAEs, Grade 3/4 clinical laboratory abnormalities, liver function tests elevations or clinically relevant ECG or vital signs changes were observed in the EDP-514 groups. 醖壓網窪壓廠選鹹窪願 (鏇製窪積窪鹽壓衊網構 ) | 积极 | 2022-06-25 | |||
Placebo | |||||||
临床1期 | HBeAg (+) | HBeAg (-) | 24 | 膚範構鹽夢膚願願願選(鏇鏇糧鏇顧鑰夢獵願鏇) = All TEAEs (n = 20) were mild except for 1 moderate event (200 mg) of abdominal pain that led to drug discontinuation, and1 severe allergic reactiontoaloe cream (800 mg). Therewerenoothergrade3TEAEsoranySAEs.Noclinicallysignificant laboratory abnormalities, liver function tests elevations or clinically relevant ECG or vital signs changes were observed. 淵獵積範衊遞膚憲觸蓋 (製夢鹹壓廠選積壓壓獵 ) | 积极 | 2022-06-25 | ||
Placebo | |||||||
临床1期 | - | 50 | 餘壓齋願齋獵製艱選選(觸築艱窪憲醖糧觸網壓) = 鏇鹹淵餘淵鬱憲淵壓齋 餘鏇艱簾選築願鹹繭積 (積憲餘範衊網夢網襯簾 ) 更多 | - | 2020-08-27 |